Chengqi Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Chengqi Yi has a total of 824 co-authors. Here are the top co-authors by number of shared publications:
- Haowei Meng
State Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking University, Beijing, China
21 shared publications Xiaoyu Li
Department of Biochemistry and Department of Gastroenterology of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
20 shared publications- Chuan He
Department of Chemistry, University of Chicago, Chicago, USA
18 shared publications Jinying Peng
State Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking University, Beijing, China
18 shared publicationsJinghui Song
State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences Peking University Beijing China
17 shared publicationsMeiling Zhang
State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, China
17 shared publications
Latest Publications
- 4 November 2026
- Published by Springer Nature in Cell Research
- p. 1-3
RNA biology and therapeutics: emerging mechanisms, technologies, and future leaders
- 4 November 2026
- Published by Springer Nature in Cell Research
- p. 1-3
RNA biology and therapeutics: emerging mechanisms, technologies, and future leaders
- 18 August 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (10) , 1250-1268
Blocking the m6Am methyltransferase PCIF1 in macrophages attenuates colitis progression by preventing neuronal damage
Macrophage–enteric neuron dialog is crucial for intestinal homeostasis, but its specific role and underlying mechanism in inflammatory bowel disease (IBD) pathogenesis remain elusive. Here, we demonstrate that colonic macrophage-mediated extracellular matrix (ECM) remodeling orchestrates enteric neuronal maturation and dictates colitis progression. The depletion of Pcif1, recognized as a unique methyltransferase for m6Am mRNA methylation, in macrophages attenuates colitis and protects enteric neurons from inflammation-driven degeneration. Specifically, Pcif1-deficient macrophages increase ECM accumulation, promoting their own extravasation into enteric neuronal plexuses and the maturation of enteric neurons, thereby curbing inflammation-driven neuronal injury and colitis progression. Mechanistically, Pcif1-mediated m6Am modification inhibits the translation of Znf219 mRNA and represses the Znf219-Egr1 axis, a master transcriptional module that governs ECM remodeling. Finally, pharmacological blockade of PCIF1 promotes macrophage-mediated ECM deposition and suppresses colitis and neuronal loss. Our findings reveal a novel mechanism whereby ECM remodeling in macrophages drives enteric neuronal maturation and illuminate the m6Am machinery as a promising therapeutic target for preventing neuronal loss in IBD patients.
- 18 August 2026
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 23 (10) , 1250-1268
Blocking the m6Am methyltransferase PCIF1 in macrophages attenuates colitis progression by preventing neuronal damage
Macrophage–enteric neuron dialog is crucial for intestinal homeostasis, but its specific role and underlying mechanism in inflammatory bowel disease (IBD) pathogenesis remain elusive. Here, we demonstrate that colonic macrophage-mediated extracellular matrix (ECM) remodeling orchestrates enteric neuronal maturation and dictates colitis progression. The depletion of Pcif1, recognized as a unique methyltransferase for m6Am mRNA methylation, in macrophages attenuates colitis and protects enteric neurons from inflammation-driven degeneration. Specifically, Pcif1-deficient macrophages increase ECM accumulation, promoting their own extravasation into enteric neuronal plexuses and the maturation of enteric neurons, thereby curbing inflammation-driven neuronal injury and colitis progression. Mechanistically, Pcif1-mediated m6Am modification inhibits the translation of Znf219 mRNA and represses the Znf219-Egr1 axis, a master transcriptional module that governs ECM remodeling. Finally, pharmacological blockade of PCIF1 promotes macrophage-mediated ECM deposition and suppresses colitis and neuronal loss. Our findings reveal a novel mechanism whereby ECM remodeling in macrophages drives enteric neuronal maturation and illuminate the m6Am machinery as a promising therapeutic target for preventing neuronal loss in IBD patients.
- Open Access
- 22 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Blocking the m6Am methyltransferase PCIF1 releases STAT1-mediated Th1 immunity to potentiate cancer immunotherapy
- 22 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessBlocking the m6Am methyltransferase PCIF1 releases STAT1-mediated Th1 immunity to potentiate cancer immunotherapy
- 22 July 2026
- Published by Springer Nature in Nature
- Vol. 656 (8127) , 463-473
Precise DNA base editing using AlphaFold3-based contact modelling
- 22 July 2026
- Published by Springer Nature in Nature
- Vol. 656 (8127) , 463-473
Precise DNA base editing using AlphaFold3-based contact modelling
- 8 July 2026
- Published by Elsevier in Developmental Cell
- Vol. 61 (7) , 1446-1470
Noncanonical caps, m6A, and Ψ RNA modifications in plant and animal development
- 8 July 2026
- Published by Elsevier in Developmental Cell
- Vol. 61 (7) , 1446-1470
Noncanonical caps, m6A, and Ψ RNA modifications in plant and animal development
- Open Access
- 16 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Quantitative analysis of small RNA pseudouridylation reveals interplay of PUS enzymes in tRNA anticodon stem-loop
Pseudouridine (Ψ) is an abundant modification in small RNA catalyzed by multiple pseudouridine synthases (PUSs). However, the substrate specificity of human PUSs remains elusive. Here, we adopted PRAISE, a quantitative Ψ detection method, to profile pseudouridylation in small RNA, including cytosolic and mitochondrial tRNAs, snRNA, and snoRNA. We found that snoRNA pseudouridylation is mediated not only by RNA-guided DKC1, but also by the stand-alone enzyme PUS7 at a specific site. Interestingly, several PUS enzymes, including PUS1, RPUSD1, and PUS7, which install nearby Ψ sites within tRNA anticodon stem-loop, can influence pseudouridylation catalyzed by other PUSs, revealing an unrecognized interplay during Ψ formation. For the three RluA family enzymes, RPUSD1 catalyzes the canonical Ψ30 in tRNA-Ile and Ψ72 in tRNA-Arg isoacceptors. RPUSD2 pseudouridylates Ψ31 of mt-tRNALeu(CUN), Ψ32 of mt-tRNAPro and mt-tRNACys, whereas RPUSD3 lacks tRNA activity. Together, our quantitative Ψ profiling characterized PUS tRNA substrates and revealed unexpected PUS interplay.
- 16 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessQuantitative analysis of small RNA pseudouridylation reveals interplay of PUS enzymes in tRNA anticodon stem-loop
Pseudouridine (Ψ) is an abundant modification in small RNA catalyzed by multiple pseudouridine synthases (PUSs). However, the substrate specificity of human PUSs remains elusive. Here, we adopted PRAISE, a quantitative Ψ detection method, to profile pseudouridylation in small RNA, including cytosolic and mitochondrial tRNAs, snRNA, and snoRNA. We found that snoRNA pseudouridylation is mediated not only by RNA-guided DKC1, but also by the stand-alone enzyme PUS7 at a specific site. Interestingly, several PUS enzymes, including PUS1, RPUSD1, and PUS7, which install nearby Ψ sites within tRNA anticodon stem-loop, can influence pseudouridylation catalyzed by other PUSs, revealing an unrecognized interplay during Ψ formation. For the three RluA family enzymes, RPUSD1 catalyzes the canonical Ψ30 in tRNA-Ile and Ψ72 in tRNA-Arg isoacceptors. RPUSD2 pseudouridylates Ψ31 of mt-tRNALeu(CUN), Ψ32 of mt-tRNAPro and mt-tRNACys, whereas RPUSD3 lacks tRNA activity. Together, our quantitative Ψ profiling characterized PUS tRNA substrates and revealed unexpected PUS interplay.
- 4 January 2026
- Published by Springer Nature in Science China Chemistry
- Vol. 69 (4) , 1676-1700
Chemical biology of precise RNA targeting and intervention: advances and perspectives
- 4 January 2026
- Published by Springer Nature in Science China Chemistry
- Vol. 69 (4) , 1676-1700
Chemical biology of precise RNA targeting and intervention: advances and perspectives
- 2 January 2026
- Published by Springer Nature in Nature Biotechnology
Single-strand deaminase-assisted editing for functional RNA manipulation
Rewriting RNA information to alter function requires controllable tools to edit RNA sequences within a user-defined region. Here we report a single-strand deaminase-assisted platform for adjustable RNA information manipulation (AIM). AIM is composed of a loop-forming guide RNA bound to an RNA-targeting Cas protein and an evolved TadA. AIM induces a loop, flanked by paired regions, in the target RNA; the loop size can be adjusted to allow conversions of single and multiple bases. We evolve TadA to achieve A-to-I, C-to-U or simultaneous A+C editing in coding and noncoding regions. We apply AIM to suppress the ochre nonsense codon (UAA) in disease-relevant cell and animal models, in which the two As must be simultaneously edited to rewrite the coding information. Moreover, we use AIM to manipulate adjacent phosphorylation sites important for protein function. Collectively, AIM is a versatile platform for manipulating RNA information within user-defined regions, opening additional avenues for functional RNA modulation.
- 2 January 2026
- Published by Springer Nature in Nature Biotechnology
Single-strand deaminase-assisted editing for functional RNA manipulation
Rewriting RNA information to alter function requires controllable tools to edit RNA sequences within a user-defined region. Here we report a single-strand deaminase-assisted platform for adjustable RNA information manipulation (AIM). AIM is composed of a loop-forming guide RNA bound to an RNA-targeting Cas protein and an evolved TadA. AIM induces a loop, flanked by paired regions, in the target RNA; the loop size can be adjusted to allow conversions of single and multiple bases. We evolve TadA to achieve A-to-I, C-to-U or simultaneous A+C editing in coding and noncoding regions. We apply AIM to suppress the ochre nonsense codon (UAA) in disease-relevant cell and animal models, in which the two As must be simultaneously edited to rewrite the coding information. Moreover, we use AIM to manipulate adjacent phosphorylation sites important for protein function. Collectively, AIM is a versatile platform for manipulating RNA information within user-defined regions, opening additional avenues for functional RNA modulation.
- Open Access
- 6 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
CRISPR-free RNA base editing mediated PTC-readthrough restores hearing in mice with Otof nonsense mutation
The gene therapy achieved by AAV-mediated otoferlin-overexpression is an effective therapeutic strategy for congenital deafness. However, achieving its physiological and endogenous patterns of expression remains challenging. Here, we generate the homologous mutation Otof c.1315 C > T (p.R439*), equivalent to OTOF c.1273 C > T (p.R425*) found in humans with profound deafness, to create a nonsense mutation-induced deaf mouse model. We then deliver the ‘RESTART v3’ system, which is a CRISPR-free RNA base editor for nonsense mutation suppression, into the cochlea of the mice. We achieve physiological otoferlin expression, and the edited premature termination codon is reverse-mutated to the original amino acid. We observe significant hearing restoration and enhancement of the behavioral auditory startle reflex. Thus, our study presents a successful RNA editing strategy to significantly restore hereditary deafness in mice carrying the specific Otof nonsense mutation, which holds great promise for future clinical translation.
- 6 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCRISPR-free RNA base editing mediated PTC-readthrough restores hearing in mice with Otof nonsense mutation
The gene therapy achieved by AAV-mediated otoferlin-overexpression is an effective therapeutic strategy for congenital deafness. However, achieving its physiological and endogenous patterns of expression remains challenging. Here, we generate the homologous mutation Otof c.1315 C > T (p.R439*), equivalent to OTOF c.1273 C > T (p.R425*) found in humans with profound deafness, to create a nonsense mutation-induced deaf mouse model. We then deliver the ‘RESTART v3’ system, which is a CRISPR-free RNA base editor for nonsense mutation suppression, into the cochlea of the mice. We achieve physiological otoferlin expression, and the edited premature termination codon is reverse-mutated to the original amino acid. We observe significant hearing restoration and enhancement of the behavioral auditory startle reflex. Thus, our study presents a successful RNA editing strategy to significantly restore hereditary deafness in mice carrying the specific Otof nonsense mutation, which holds great promise for future clinical translation.
- Open Access
- 31 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (44) , eadx6809
Pt-seq unveils the genomic binding pattern of platinum-based drugs
Platinum-based drugs (Pt drugs) are widely used in cancer chemotherapy, yet their genome-wide binding patterns remain incompletely understood. Here, we present Pt sequencing (Pt-seq), an antibody-assisted, genome-wide method for mapping Pt-DNA adducts at single-base resolution. By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. Using Pt-seq, we identified tens to hundreds of binding clusters that are 10 to 20 kilobases in median length and highly consistent among different drugs, predominantly localizing to centromeric and ribosomal DNA regions. In cisplatin-resistant cells, we found significantly reduced binding within these regions. Moreover, we found that mutations in cancer cells can generate previously unidentified binding sites. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatin-DNA binding and sensitizes cells to cisplatin. Collectively, Pt-seq sensitively profiles Pt–DNA interactions and deepens our understanding of the genome-wide effect of chemotherapeutic drugs.
- 31 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (44) , eadx6809
Open AccessPt-seq unveils the genomic binding pattern of platinum-based drugs
Platinum-based drugs (Pt drugs) are widely used in cancer chemotherapy, yet their genome-wide binding patterns remain incompletely understood. Here, we present Pt sequencing (Pt-seq), an antibody-assisted, genome-wide method for mapping Pt-DNA adducts at single-base resolution. By using exo- and endonucleases to remove background, Pt-seq enables robust and sensitive profiling of binding sites for cisplatin, oxaliplatin, lobaplatin, and a Pt(IV) complex. Using Pt-seq, we identified tens to hundreds of binding clusters that are 10 to 20 kilobases in median length and highly consistent among different drugs, predominantly localizing to centromeric and ribosomal DNA regions. In cisplatin-resistant cells, we found significantly reduced binding within these regions. Moreover, we found that mutations in cancer cells can generate previously unidentified binding sites. On this basis, we demonstrated that ICR-191, an acridine orange compound capable of inducing G insertions, enhances cisplatin-DNA binding and sensitizes cells to cisplatin. Collectively, Pt-seq sensitively profiles Pt–DNA interactions and deepens our understanding of the genome-wide effect of chemotherapeutic drugs.